Philips, Ypsomed pair up on cloud-connected delivery devices for RA, MS and diabetes

The Switzerland-based Ypsomed Group supplies pens, autoinjectors and infusion hardware to pharmaceutical companies, as well as directly to patients for at-home use. (Philips)

Royal Philips plans to team up with Ypsomed to install digital, self-medication adherence tracking across a line of connected liquid drug delivery devices, including injection and infusion systems used in diabetes, multiple sclerosis and rheumatoid arthritis.

The two companies signed a memorandum of understanding to build out Ypsomed’s new SmartServices platform, based on Philips’ cloud-based HealthSuite, to offer value-added products to the industry and extend Ypsomed’s medical device business.

The Switzerland-based Ypsomed Group supplies pens, autoinjectors and infusion hardware to pharmaceutical companies, as well as directly to patients for at-home use. The companies aim to sign a definitive agreement before the end of the year.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Our partnership with Philips aims at embedding smart devices in a digital health ecosystem that simplifies access to therapy-relevant medication adherence data,” said Ulrike Bauer, senior VP at Ypsomed Delivery Systems.

RELATED: Philips inks 11-year deal for patient monitoring as a service

“This will allow our pharmaceutical customers to focus on building therapy-specific digital solutions for patients, caregivers and physicians,” Bauer said.

“It will shorten time-to-market, enable them to scale-up solutions in a secure HIPAA-compliant way, and allow them to integrate data from Ypsomed devices with other data sources to support many different value-added use cases,” added Dale Wiggins, business leader for the HealthSuite platform at Philips.

Ypsomed’s portfolio includes the consumer-focused mylife Diabetescare brand, as well as YDS Ypsomed Delivery Systems for business-to-business sales.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.